BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008;47:605-612. [PMID: 18157835 DOI: 10.1002/hep.22044] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 7.2] [Reference Citation Analysis]
Number Citing Articles
1 Aghemo A, Bhoori S, De Nicola S, Mazzaferro V, Colombo M. Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. Hepat Mon 2012;12:411-4. [PMID: 22879832 DOI: 10.5812/hepatmon.6135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
2 Gomez EV, Perez YM, Sanchez HV, Forment GR, Soler EA, Bertot LC, Garcia AY, del Rosario Abreu Vazquez M, Fabian LG. Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C. World J Gastroenterol 2010; 16(21): 2638-2647 [PMID: 20518086 DOI: 10.3748/wjg.v16.i21.2638] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
3 Imamoto R, Okano JI, Sawada S, Fujise Y, Abe R, Murawaki Y. Null anticarcinogenic effect of silymarin on diethylnitrosamine-induced hepatocarcinogenesis in rats. Exp Ther Med 2014;7:31-8. [PMID: 24348760 DOI: 10.3892/etm.2013.1391] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
4 Lovelace ES, Maurice NJ, Miller HW, Slichter CK, Harrington R, Magaret A, Prlic M, De Rosa S, Polyak SJ. Silymarin suppresses basal and stimulus-induced activation, exhaustion, differentiation, and inflammatory markers in primary human immune cells. PLoS One 2017;12:e0171139. [PMID: 28158203 DOI: 10.1371/journal.pone.0171139] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
5 Richmond JA, Bailey DE, Patel K, Jezsik JA, Muir A, Lin J, Chow S, Uzarski D, Mchutchison JG. The use of complementary and alternative medicine by patients with chronic hepatitis C. Complementary Therapies in Clinical Practice 2010;16:124-31. [DOI: 10.1016/j.ctcp.2009.10.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
6 Henson JB, Brown CL, Chow SC, Muir AJ. Complementary and Alternative Medicine Use in United States Adults With Liver Disease. J Clin Gastroenterol 2017;51:564-70. [PMID: 27479144 DOI: 10.1097/MCG.0000000000000617] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
7 Okano JI, Fujise Y, Abe R, Imamoto R, Murawaki Y. Chemoprevention against hepatocellular carcinoma. Clin J Gastroenterol 2011;4:185-97. [PMID: 26189518 DOI: 10.1007/s12328-011-0227-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
8 Loguercio C, Festi D. Silybin and the liver: From basic research to clinical practice. World J Gastroenterol 2011; 17(18): 2288-2301 [PMID: 21633595 DOI: 10.3748/wjg.v17.i18.2288] [Cited by in CrossRef: 200] [Cited by in F6Publishing: 170] [Article Influence: 20.0] [Reference Citation Analysis]
9 Teissier E, Penin F, Pécheur EI. Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules 2010;16:221-50. [PMID: 21193846 DOI: 10.3390/molecules16010221] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
10 Pan P, Wang J, Luo J, Wang S, Zhou Y, Chen S, Du Z. Silibinin affects the pharmacokinetics of methadone in rats. Drug Test Anal 2018;10:557-61. [DOI: 10.1002/dta.2235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
11 Rehan HS, Chopra D, Yadav M, Wardhan N, Manak S, Siddiqui KM, Aslam M. Safety and efficacy of Qurse-e-istisqua in chronic hepatitis C infection: an exploratory study. Indian J Pharmacol 2015;47:72-9. [PMID: 25821315 DOI: 10.4103/0253-7613.150347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kiser JJ, Burton JR Jr, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013;10:596-606. [PMID: 23817323 DOI: 10.1038/nrgastro.2013.106] [Cited by in Crossref: 96] [Cited by in F6Publishing: 88] [Article Influence: 12.0] [Reference Citation Analysis]
13 Rossi S, Navarro VJ. Herbs and liver injury: a clinical perspective. Clin Gastroenterol Hepatol. 2014;12:1069-1076. [PMID: 23924877 DOI: 10.1016/j.cgh.2013.07.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
14 Azocar J, Diaz A. Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection. World J Gastroenterol 2013; 19(7): 1085-1090 [PMID: 23467073 DOI: 10.3748/wjg.v19.i7.1085] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
15 Nadeem AE, Thomas P, Ulf ML, Elena N, Anggakusuma A, Mohamed BM, Frank P, Patrick B. Cell culture-derived HCV cannot infect synovial fibroblasts. Sci Rep 2015;5:18043. [PMID: 26643193 DOI: 10.1038/srep18043] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
16 Brantley SJ, Graf TN, Oberlies NH, Paine MF. A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab Dispos 2013;41:1662-70. [PMID: 23801821 DOI: 10.1124/dmd.113.052563] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
17 Murtaza G, Ullah N, Mukhtar F, Nawazish S, Muneer S; Mariam. Phytotherapeutics: The Emerging Role of Intestinal and Hepatocellular Transporters in Drug Interactions with Botanical Supplements. Molecules 2017;22:E1699. [PMID: 29065448 DOI: 10.3390/molecules22101699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
18 Mehrab-Mohseni M, Sendi H, Steuerwald N, Ghosh S, Schrum LW, Bonkovsky HL. Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV. World J Gastroenterol 2011; 17(13): 1694-1700 [PMID: 21483629 DOI: 10.3748/wjg.v17.i13.1694] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
19 Yang Z, Zhuang L, Lu Y, Xu Q, Chen X. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. Biomed Res Int 2014;2014:941085. [PMID: 25247194 DOI: 10.1155/2014/941085] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
20 Corsini A, Bortolini M. Drug-induced liver injury: the role of drug metabolism and transport. J Clin Pharmacol. 2013;53:463-474. [PMID: 23436293 DOI: 10.1002/jcph.23] [Cited by in Crossref: 84] [Cited by in F6Publishing: 75] [Article Influence: 10.5] [Reference Citation Analysis]
21 Hawke RL, Schrieber SJ, Soule TA, Wen Z, Smith PC, Reddy KR, Wahed AS, Belle SH, Afdhal NH, Navarro VJ. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010;50:434-449. [PMID: 19841158 DOI: 10.1177/0091270009347475] [Cited by in Crossref: 90] [Cited by in F6Publishing: 87] [Article Influence: 7.5] [Reference Citation Analysis]
22 Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734. [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 16.8] [Reference Citation Analysis]
23 Lovelace ES, Polyak SJ. Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection. Viruses 2015;7:6218-32. [PMID: 26633463 DOI: 10.3390/v7122933] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
24 Polyak SJ, Ferenci P, Pawlotsky JM. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology. 2013;57:1262-1271. [PMID: 23213025 DOI: 10.1002/hep.26179] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 9.3] [Reference Citation Analysis]
25 Dunnick JK, Singh B, Nyska A, Peckham J, Kissling GE, Sanders JM. Investigating the potential for toxicity from long-term use of the herbal products, goldenseal and milk thistle. Toxicol Pathol 2011;39:398-409. [PMID: 21300790 DOI: 10.1177/0192623310394211] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
26 Néant N, Solas C. Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection. Int J Antimicrob Agents 2020;56:105571. [PMID: 30394302 DOI: 10.1016/j.ijantimicag.2018.10.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Reddy BU, Mullick R, Kumar A, Sharma G, Bag P, Roy CL, Sudha G, Tandon H, Dave P, Shukla A, Srinivasan P, Nandhitha M, Srinivasan N, Das S. A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage. Antiviral Research 2018;150:47-59. [DOI: 10.1016/j.antiviral.2017.12.004] [Reference Citation Analysis]
28 Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis - a practical guide. Aliment Pharmacol Ther. 2013;37:1132-1156. [PMID: 23638982 DOI: 10.1111/apt.12324] [Cited by in Crossref: 108] [Cited by in F6Publishing: 87] [Article Influence: 13.5] [Reference Citation Analysis]
29 Seeff LB, Ghany MG. Management of untreated and nonresponder patients with chronic hepatitis C. Semin Liver Dis 2010;30:348-60. [PMID: 20960375 DOI: 10.1055/s-0030-1267536] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
30 Flores A, Nustas R, Nguyen HL, Rahimi RS. Severe Cholestasis and Bile Acid Nephropathy From Anabolic Steroids Successfully Treated With Plasmapheresis. ACG Case Rep J 2016;3:133-5. [PMID: 26958570 DOI: 10.14309/crj.2016.24] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
31 Malaguarnera G, Bertino G, Chisari G, Motta M, Vecchio M, Vacante M, Caraci F, Greco C, Drago F, Nunnari G, Malaguarnera M. Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability. BMC Psychiatry 2016;16:398. [PMID: 27842532 DOI: 10.1186/s12888-016-1115-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
32 Mehrab-Mohseni M, Sendi H, Steuerwald N, Ghosh S, Schrum LW, Bonkovsky HL. Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV. World J Gastroenterol. 2011;17:1694-1700. [PMID: 21483629 DOI: 10.378/wjg.v17.i13.1694] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Polyak SJ, Morishima C, Hawke R. Antiviral effects of silymarin against hepatitis C: the jury is still out. Hepatology 2008;48:345-6. [PMID: 18509876 DOI: 10.1002/hep.22235] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
34 Kumar V, Ahmad A. Role of MAIT cells in the immunopathogenesis of inflammatory diseases: New players in old game. Int Rev Immunol 2018;37:90-110. [PMID: 29106304 DOI: 10.1080/08830185.2017.1380199] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
35 Miranda SR, Lee JK, Brouwer KL, Wen Z, Smith PC, Hawke RL. Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2). Drug Metab Dispos 2008;36:2219-26. [PMID: 18687803 DOI: 10.1124/dmd.108.021790] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
36 Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74. [PMID: 19330875 DOI: 10.1002/hep.22759] [Cited by in Crossref: 2134] [Cited by in F6Publishing: 1936] [Article Influence: 177.8] [Reference Citation Analysis]
37 McClure J, Lovelace ES, Elahi S, Maurice NJ, Wagoner J, Dragavon J, Mittler JE, Kraft Z, Stamatatos L, Horton H, De Rosa SC, Coombs RW, Polyak SJ. Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation. PLoS One 2012;7:e41832. [PMID: 22848626 DOI: 10.1371/journal.pone.0041832] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
38 Del Prete A, Scalera A, Iadevaia MD, Miranda A, Zulli C, Gaeta L, Tuccillo C, Federico A, Loguercio C. Herbal products: benefits, limits, and applications in chronic liver disease. Evid Based Complement Alternat Med. 2012;2012:837939. [PMID: 22991573 DOI: 10.1155/2012/837939] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
39 Guan YS, He Q. Plants Consumption and Liver Health. Evid Based Complement Alternat Med 2015;2015:824185. [PMID: 26221179 DOI: 10.1155/2015/824185] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
40 Hong M, Li S, Tan HY, Wang N, Tsao SW, Feng Y. Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects. Int J Mol Sci 2015;16:28705-45. [PMID: 26633388 DOI: 10.3390/ijms161226126] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 13.5] [Reference Citation Analysis]
41 El-Tantawy WH, Temraz A. Natural products for the management of the hepatitis C virus: a biochemical review. Arch Physiol Biochem 2020;126:116-28. [PMID: 30269604 DOI: 10.1080/13813455.2018.1498902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Lee V, Goyal A, Hsu CC, Jacobson JS, Rodriguez RD, Siegel AB. Dietary supplement use among patients with hepatocellular carcinoma. Integr Cancer Ther 2015;14:35-41. [PMID: 25228537 DOI: 10.1177/1534735414550038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
43 Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pécheur EI, Tavis JE, Polyak SJ. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One. 2011;6:e16464. [PMID: 21297992 DOI: 10.1371/journal.pone.0016464] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
44 Mohammad RA, Bulloch MN, Chan J, Deming P, Love B, Smith L, Dong BJ, GI Liver Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy 2014;34:1341-54. [PMID: 25359244 DOI: 10.1002/phar.1512] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
45 Mori N, Nakasone K, Tomimori K, Ishikawa C. Beneficial effects of fucoidan in patients with chronic hepatitis C virus infection. World J Gastroenterol 2012; 18(18): 2225-2230 [PMID: 22611316 DOI: 10.3748/wjg.v18.i18.2225] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
46 Napolitano JG, Lankin DC, Graf TN, Friesen JB, Chen SN, McAlpine JB, Oberlies NH, Pauli GF. HiFSA fingerprinting applied to isomers with near-identical NMR spectra: the silybin/isosilybin case. J Org Chem 2013;78:2827-39. [PMID: 23461697 DOI: 10.1021/jo302720h] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 9.1] [Reference Citation Analysis]
47 El-yazbi AF, Khalifa Y, Elkhatib MA, El-yazbi AF. Green analytical method for the determination of sofosbuvir, ledipasvir, ribavirin and complex silymarin flavonoids simultaneously in biological fluids. Microchemical Journal 2021;164:105964. [DOI: 10.1016/j.microc.2021.105964] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
48 Marzio DLHD, Fenkel JM. Complementary and alternative medications in hepatitis C infection. World J Hepatol 2014; 6(1): 9-16 [PMID: 24653790 DOI: 10.4254/wjh.v6.i1.9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
49 Reddy BU, Mullick R, Kumar A, Sharma G, Bag P, Roy CL, Sudha G, Tandon H, Dave P, Shukla A, Srinivasan P, Nandhitha M, Srinivasan N, Das S. A natural small molecule inhibitor corilagin blocks HCV replication and modulates oxidative stress to reduce liver damage. Antiviral Res 2018;150:47-59. [PMID: 29224736 DOI: 10.1016/j.antiviral.2017.12.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
50 Hofmann WP, Zeuzem S. New therapeutic strategies needed for advanced disease. Nat Rev Gastroenterol Hepatol 2009;6:325-7. [DOI: 10.1038/nrgastro.2009.63] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
51 Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, Sloan DD, Graf TN, Oberlies NH, Lee DY. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology. 2010;138:671-681, 681.e1-2. [PMID: 19782083 DOI: 10.1053/j.gastro.2009.09.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 67] [Article Influence: 6.2] [Reference Citation Analysis]
52 Seeff L, Stickel F, Navarro VJ. Hepatotoxicity of Herbals and Dietary Supplements. Drug-Induced Liver Disease. Elsevier; 2013. pp. 631-57. [DOI: 10.1016/b978-0-12-387817-5.00035-2] [Cited by in Crossref: 7] [Article Influence: 0.9] [Reference Citation Analysis]
53 Snow KK, Bell MC, Stoddard AM, Curto TM, Wright EC, Dienstag JL. Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials 2014;15:159. [PMID: 24886378 DOI: 10.1186/1745-6215-15-159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
54 Xu W, Zhu H, Hu B, Cheng Y, Guo Y, Yao W, Qian H. Echinacea in hepatopathy: A review of its phytochemistry, pharmacology, and safety. Phytomedicine 2021;87:153572. [PMID: 34029938 DOI: 10.1016/j.phymed.2021.153572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 McGill MR, Du K, Weemhoff JL, Jaeschke H. Critical review of resveratrol in xenobiotic-induced hepatotoxicity. Food Chem Toxicol 2015;86:309-18. [PMID: 26561740 DOI: 10.1016/j.fct.2015.11.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
56 Akram M, Tahir IM, Shah SMA, Mahmood Z, Altaf A, Ahmad K, Munir N, Daniyal M, Nasir S, Mehboob H. Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review. Phytother Res 2018;32:811-22. [PMID: 29356205 DOI: 10.1002/ptr.6024] [Cited by in Crossref: 81] [Cited by in F6Publishing: 62] [Article Influence: 27.0] [Reference Citation Analysis]
57 丁天鹏, 曲颖, 陆伦根, 施根林, 王若飞. 18α甘草酸对CCl4诱导的肝纤维化大鼠氧化应激的影响. 世界华人消化杂志 2012; 20(20): 1819-1823 [DOI: 10.11569/wcjd.v20.i20.1819] [Reference Citation Analysis]
58 Pal S, Polyak SJ, Bano N, Qiu WC, Carithers RL, Shuhart M, Gretch DR, Das A. Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. J Gastroenterol Hepatol. 2010;25:627-634. [PMID: 20074151 DOI: 10.1111/j.1440-1746.2009.06128.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 7.7] [Reference Citation Analysis]
59 Seeff LB, Bonkovsky HL, Navarro VJ, Wang G. Herbal products and the liver: a review of adverse effects and mechanisms. Gastroenterology. 2015;148:517-532.e3. [PMID: 25500423 DOI: 10.1053/j.gastro.2014.12.004] [Cited by in Crossref: 64] [Cited by in F6Publishing: 51] [Article Influence: 9.1] [Reference Citation Analysis]
60 Navarro VJ, Seeff LB. Liver injury induced by herbal complementary and alternative medicine. Clin Liver Dis. 2013;17:715-735, x. [PMID: 24099027 DOI: 10.1016/j.cld.2013.07.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
61 Riebensahm C, Ka D, Sow A, Semmo N, Wandeler G. A closer look at the spectrum of drug-induced liver injury in sub-Saharan Africa. Expert Rev Clin Pharmacol 2019;12:875-83. [PMID: 31269818 DOI: 10.1080/17512433.2019.1638251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Yu HH, Qiu YX, Li B, Peng CY, Zeng R, Wang W. Kadsura heteroclita stem ethanol extract protects against carbon tetrachloride-induced liver injury in mice via suppression of oxidative stress, inflammation, and apoptosis. J Ethnopharmacol. 2021;267:113496. [PMID: 33091494 DOI: 10.1016/j.jep.2020.113496] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
63 Xie Y, Miranda SR, Hoskins JM, Hawke RL. Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD. Molecules 2017;22:E142. [PMID: 28098838 DOI: 10.3390/molecules22010142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
64 Freedman ND, Curto TM, Morishima C, Seeff Lb, Goodman ZD, Wright EC, Sinha R, Everhart JE, the HALT-C Trial Group. Silymarin use and liver disease progression in the HALT-C trial. Aliment Pharmaol Ther. 2011;33:127-137. [PMID: 21083592 DOI: 10.1111/j.1365-2036.2010.04503.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
65 Langness JA, Everson GT. Viral hepatitis: Drug-drug interactions in HCV treatment--the good, the bad and the ugly. Nat Rev Gastroenterol Hepatol 2016;13:194-5. [PMID: 26882885 DOI: 10.1038/nrgastro.2016.24] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
66 Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos 2014;42:301-17. [PMID: 24335390 DOI: 10.1124/dmd.113.055236] [Cited by in Crossref: 104] [Cited by in F6Publishing: 87] [Article Influence: 13.0] [Reference Citation Analysis]
67 Strader DB, Navarro VJ, Seeff LB. Hepatotoxicity of Herbal Preparations. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 462-75. [DOI: 10.1016/b978-1-4377-0881-3.00026-7] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
68 Ferrucci LM, Bell BP, Dhotre KB, Manos MM, Terrault NA, Zaman A, Murphy RC, Vanness GR, Thomas AR, Bialek SR, Desai MM, Sofair AN. Complementary and alternative medicine use in chronic liver disease patients. J Clin Gastroenterol 2010;44:e40-5. [PMID: 19779363 DOI: 10.1097/MCG.0b013e3181b766ed] [Cited by in Crossref: 37] [Cited by in F6Publishing: 7] [Article Influence: 3.4] [Reference Citation Analysis]
69 El-Kamary SS, Shardell MD, Abdel-Hamid M, Ismail S, El-Ateek M, Metwally M, Mikhail N, Hashem M, Mousa A, Aboul-Fotouh A. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009;16:391-400. [PMID: 19303273 DOI: 10.1016/j.phymed.2009.02.002] [Cited by in Crossref: 61] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
70 Gupta NK, Lewis JH. Review article: The use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther. 2008;28:1021-1041. [PMID: 18671777 DOI: 10.1111/j.1365-2036.2008.03822.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
71 Payen J, Pillard F, Mascarell V, Rivière D, Couzigou P, Kharlov N. Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavarin therapy? Gastroentérologie Clinique et Biologique 2009;33:8-14. [DOI: 10.1016/j.gcb.2008.10.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
72 Yasutake K, Kohjima M, Nakashima M, Kotoh K, Nakamuta M, Enjoji M. Nutrition therapy for liver diseases based on the status of nutritional intake. Gastroenterol Res Pract 2012;2012:859697. [PMID: 23197979 DOI: 10.1155/2012/859697] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
73 Fried MW, Navarro VJ, Afdhal N, Belle SH, Wahed AS, Hawke RL, Doo E, Meyers CM, Reddy KR. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA. 2012;308:274-282. [PMID: 22797645 DOI: 10.1001/jama.2012.8265] [Cited by in Crossref: 99] [Cited by in F6Publishing: 81] [Article Influence: 11.0] [Reference Citation Analysis]
74 Hackett ES, Twedt DC, Gustafson DL. Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease. J Vet Intern Med. 2013;27:10-16. [PMID: 23140176 DOI: 10.1111/jvim.12002] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
75 Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, Grove J, Brimacombe C, McKeating JA. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology. 2010;51:1912-1921. [PMID: 20512985 DOI: 10.1002/hep.23587] [Cited by in Crossref: 139] [Cited by in F6Publishing: 136] [Article Influence: 12.6] [Reference Citation Analysis]
76 Seeff LB. Are herbals as safe as their advocates believe? J Hepatol. 2009;50:13-16. [PMID: 19017552 DOI: 10.1016/j.jhep.2008.10.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
77 Polyak SJ, Oberlies NH, Pécheur EI, Dahari H, Ferenci P, Pawlotsky JM. Silymarin for HCV infection. Antivir Ther 2013;18:141-7. [PMID: 23011959 DOI: 10.3851/IMP2402] [Cited by in Crossref: 44] [Cited by in F6Publishing: 21] [Article Influence: 4.9] [Reference Citation Analysis]
78 Guedj J, Dahari H, Pohl RT, Ferenci P, Perelson AS. Understanding silibinin's modes of action against HCV using viral kinetic modeling. J Hepatol 2012;56:1019-24. [PMID: 22245888 DOI: 10.1016/j.jhep.2011.12.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
79 Bonifaz V, Shan Y, Lambrecht RW, Donohue SE, Moschenross D, Bonkovsky HL. Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells. Liver Int 2009;29:366-73. [PMID: 18694403 DOI: 10.1111/j.1478-3231.2008.01833.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
80 Viktorova J, Stranska-Zachariasova M, Fenclova M, Vitek L, Hajslova J, Kren V, Ruml T. Complex Evaluation of Antioxidant Capacity of Milk Thistle Dietary Supplements. Antioxidants (Basel) 2019;8:E317. [PMID: 31426591 DOI: 10.3390/antiox8080317] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
81 Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH. Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci USA. 2010;107:5995-5999. [PMID: 20231449 DOI: 10.1073/pnas.0914009107] [Cited by in Crossref: 177] [Cited by in F6Publishing: 163] [Article Influence: 16.1] [Reference Citation Analysis]
82 Hellerbrand C, Schattenberg JM, Peterburs P, Lechner A, Brignoli R. The potential of silymarin for the treatment of hepatic disorders. Clin Phytosci 2017;2. [DOI: 10.1186/s40816-016-0019-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 4.2] [Reference Citation Analysis]
83 Yan T, Yan N, Wang P, Xia Y, Hao H, Wang G, Gonzalez FJ. Herbal drug discovery for the treatment of nonalcoholic fatty liver disease. Acta Pharm Sin B 2020;10:3-18. [PMID: 31993304 DOI: 10.1016/j.apsb.2019.11.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
84 Köck K, Xie Y, Hawke RL, Oberlies NH, Brouwer KL. Interaction of silymarin flavonolignans with organic anion-transporting polypeptides. Drug Metab Dispos 2013;41:958-65. [PMID: 23401473 DOI: 10.1124/dmd.112.048272] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
85 Larrey D, Faure S. Herbal medicine hepatotoxicity: A new step with development of specific biomarkers. Journal of Hepatology 2011;54:599-601. [DOI: 10.1016/j.jhep.2010.12.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
86 Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, Cursaro C, Danila M, de Sio I, Floreani A, Freni MA, Grieco A, Groppo M, Lazzari R, Lobello S, Lorefice E, Margotti M, Miele L, Milani S, Okolicsanyi L, Palasciano G, Portincasa P, Saltarelli P, Smedile A, Somalvico F, Spadaro A, Sporea I, Sorrentino P, Vecchione R, Tuccillo C, Blanco CDV, Federico A. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radical Biology and Medicine 2012;52:1658-65. [DOI: 10.1016/j.freeradbiomed.2012.02.008] [Cited by in Crossref: 135] [Cited by in F6Publishing: 122] [Article Influence: 15.0] [Reference Citation Analysis]